H3K18 Lactylation Drives CD8⁺ T Cell Exclusion and Anti-PD-1 Resistance in Hepatocellular Carcinoma

Investigators identified H3 lysine 9 lactylation (H3K9la) as a potential key target for driving resistance to anti-PD-1 immunotherapy in HCC.